Skip to content

Nuvation Bio NUVB Free cash flow

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Pfizer logo
PfizerPFE
$2.18B+23.0%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$78.68M+28.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$138M-3.8%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$76.14M-23.5%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Calculated from Nuvation Bio’s reported figures.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's free cash flow?
Nuvation Bio (NUVB) reported free cash flow of $5.02M in Q1 2026.
How has Nuvation Bio's free cash flow changed year-over-year?
Nuvation Bio's free cash flow increased by 111.8% year-over-year, from -$42.7M to $5.02M.
What is the long-term trend for Nuvation Bio's free cash flow?
Over 4 years (2021 to 2025), Nuvation Bio's free cash flow has grown at a 27.6% compound annual growth rate (CAGR), from -$68.47M to -$181.43M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.